KRAS has been characterized as a cancer-related gene with potential importance for future cancer treatment [44], [45], [46], while RAD51 and XRCC3 polymorphisms may be associated with an increased risk of prostate cancer [47]. Here, RAD51 is linked to prostate cancer.